Mechanistically, IR-546 activated GSK-3β Ser9 phosphorylation, which suppressed β-catenin and its downstream proteins in vitro and in vivo, thereby inhibiting melanoma growth through suppression of the AKT/GSK-3β/β-catenin pathway. The gene discussed is GSK3B; the disease is melanoma.